NHS Logo
Bedfordshire and Luton Joint Formulary
Bedfordshire Hospitals NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes ICB
Formulary items found
Status Description Section
Amber SPAAlpha Tocopheryl Acetate 500mg /5mL
(Suspension) 		Nutrition and blood, Vitamin E, 09.06.05
GREENCarbomer 0.2%  Eye, Tear deficiency, ocular lubricants, and astringents, 11.08.01
 Colistimethate Sodium 1 & 2 million units Colomycin®
(Injection which can be nebulised) 		Infections, Polymyxins, 05.01.07
REDDornase Alfa 2.5mg (2500 units) / 2.5mL Pulmozyme®
(Nebuliser Solution) 		Respiratory system, Dornase alfa, 03.07
REDTobramycin 300mg/4mL
(Nebuliser Solution) 		Infections, Aminoglycosides, 05.01.04
REDTobramycin inhaler 28mg TOBI Podhaler®
(Dry powder for inhalation) 		Infections, Aminoglycosides, 05.01.04
Amber SPAVitamin and Mineral Supplement DEKAs® Plus
(Softgel capsules , chewable tablets , paediatric liquid ) 		A2 - Borderline substances, Vitamin and Mineral supplements, A2.04.02
Amber SPAVitamins ADEK capsules Paravit CF®
(For Cystic Fibrosis) 		A2 - Borderline substances, Vitamin and Mineral supplements, A2.04.02
Searchiing the National BNF we found these items - Click button under Local to search local formulary or BNF to view on online BNF.
Local BNF Section
Deutivacaftor Deutivacaftor With Tezacaftor And Vanzacaftor Respiratory System, Mucolytics
Conditions Affecting Sputum Viscosity, Cystic Fibrosis
Dornase  Dornase Alfa Respiratory System, Mucolytics
Conditions Affecting Sputum Viscosity, Cystic Fibrosis
Ivacaftor  Ivacaftor Respiratory System, Mucolytics
Conditions Affecting Sputum Viscosity, Cystic Fibrosis
Ivacaftor  Ivacaftor With Tezacaftor And Elexacaftor Respiratory System, Mucolytics
Conditions Affecting Sputum Viscosity, Cystic Fibrosis
Lumacaftor Lumacaftor With Ivacaftor Respiratory System, Mucolytics
Conditions Affecting Sputum Viscosity, Cystic Fibrosis
Mannitol Mannitol Respiratory System, Diuretics, Osmotic Diuretics
Conditions Affecting Sputum Viscosity, Cystic Fibrosis
Mannitol Mannitol Respiratory System, Mucolytics
Conditions Affecting Sputum Viscosity, Cystic Fibrosis
Tezacaftor Tezacaftor With Ivacaftor Respiratory System, Mucolytics
Conditions Affecting Sputum Viscosity, Cystic Fibrosis
Selecting a button in the local column will search the local formulary again for the word on the button. Where the button is in outline no local match at drug name level was found.
Links found
JPC Bulletin: Use of Nebulised Tobramycin and Nebulised Colistimethate sodium as Antibiotic Prophylaxis to prevent exacerbations of Non- Cystic Fibrosis Bronchiectasis in Adult Patients
NICE NG78: Cystic fibrosis: diagnosis and management. October 2017
NICE TA1085: Vanzacaftor-tezacaftor-deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over
NICE TA266 Cystic fibrosis - mannitol dry powder for inhalation (TA266)
NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin
NICE TA988 Evidence-based recommendations on ivacaftor–tezacaftor–elexacaftor (Kaftrio) plus ivacaftor (Kalydeco), tezacaftor–ivacaftor (Symkevi) plus ivacaftor, and lumacaftor–ivacaftor (Orkambi) for treating cystic fibrosis.